Imunon (Nasdaq:IMNN) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

IMNN 주식 개요

임상 단계의 생명공학 회사인 이뮤논은 암과 전염병 치료를 위한 면역 치료제와 백신을 개발하는 기업입니다.

IMNN 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

위험 분석

최근 3개월간 주가 변동폭 심해

지난 1년 동안 주주가 크게 희석되었습니다.

수익이 1백만 달러 미만인 경우 ( $0 )

수익은 향후 3년간 연평균 22% 씩 감소할 것으로 예상됩니다.

+ 2 더 많은 위험

Imunon, Inc. 경쟁사

Unity Biotechnology

NasdaqGS:UBX

US$24.4m

iBio

NYSEAM:IBIO

US$18.0m

Kazia Therapeutics

NasdaqCM:KZIA

US$11.7m

AgeX Therapeutics

NYSEAM:AGE

US$31.5m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Imunon
과거 주가
현재 주가	US$1.06
52주 최고치	US$3.65
52주 최저치	US$0.48
베타	2.13
11개월 변경	-7.83%
3개월 변경 사항	-14.52%
1년 변경 사항	1.92%
33년 변화	-92.37%
5년 변화	-95.96%
IPO 이후 변화	-99.99%

최근 뉴스 및 업데이트

Recent updates

Celsion changes name to Imunon (IMNN)

Sep 19

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

Sep 01

주주 수익률

	IMNN	US Biotechs	US 마켓
7D	2.9%	-0.1%	0.8%
1Y	1.9%	21.7%	33.4%

수익률 대 산업: IMNN 지난 1년 동안 15.1 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: IMNN 지난 1년 동안 20.5 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is IMNN's price volatile compared to industry and market?
IMNN volatility
IMNN Average Weekly Movement	54.4%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.1%

안정적인 주가: IMNN 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: IMNN 의 주간 변동성은 지난 1년 동안 29% 에서 52% 로 증가했습니다.

회사 소개

설립	직원	CEO	웹사이트
1982	33	Stacy Lindborg	imunon.com

임상 단계의 생명공학 회사인 이뮤논은 암과 전염병 치료를 위한 면역 요법과 백신을 개발하는 회사입니다. 이뮤논의 주요 임상 프로그램은 난소암의 국소 치료를 위한 DNA 기반 면역 요법인 IMNN-001로, 임상 2상 개발 중입니다. 전임상 단계의 제품으로는 코로나19 부스터 백신인 IMNN-101, 라사 바이러스 치료를 위한 IMNN-102, 흑색종에 대한 Trp2 종양 관련 항원 암 백신인 IMNN-201 등이 있습니다.

Imunon, Inc. 기본 사항 요약

Imunon 의 수익과 매출은 시가총액과 어떻게 비교하나요?
IMNN 기본 통계
시가총액	US$14.98m
수익(TTM)	-US$18.08m
수익(TTM)	n/a

0.0x

P/S 비율

-0.8x

P/E 비율

IMNN 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
IMNN 손익 계산서(TTM)
수익	US$0
수익 비용	US$359.30k
총 이익	-US$359.30k
기타 비용	US$17.72m
수익	-US$18.08m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.26
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

IMNN 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

IMNN 주식 개요

보상

위험 분석

Imunon, Inc. 경쟁사

NasdaqGS:UBX

US$24.4m

NYSEAM:IBIO

US$18.0m

NasdaqCM:KZIA

US$11.7m

NYSEAM:AGE

US$31.5m

가격 내역 및 성능

최근 뉴스 및 업데이트

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Price target decreased by 11% to US$9.75

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

Recent updates

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Price target decreased by 11% to US$9.75

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial

Price target decreased by 17% to US$10.00

IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New minor risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

New minor risk - Share price stability

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Consensus EPS estimates upgraded to US$2.95 loss

Price target decreased by 19% to US$18.75

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Price target decreased to US$24.00

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion changes name to Imunon (IMNN)

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

First half 2022 earnings: EPS and revenues exceed analyst expectations

Celsion Q2 2022 Earnings Preview

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion adds Moderna chief commercial officer as CEO

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Celsion Corporation, Annual General Meeting, Jun 13, 2022

Price target decreased to US$32.67

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial At 2022 Aacr Annual Meeting

Celsion Corporation has completed a Follow-on Equity Offering in the amount of $7.000004 million.

Price target decreased to US$41.00

Full year 2021 earnings: EPS misses analyst expectations

Celsion Corporation Reports Impairment for the Fourth Quarter Ended December 31, 2021

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer